Detailed paper information

Back to list

Paper title Regulation of glioma cell invasion by 3q26 gene products PIK3CA, SOX2 and OPA1
Paper code P48
  1. Archana Ramadoss University of Basel
  2. Severina Leu University Hospital Basel Speaker
  3. Thorsten Schaefer University Hospital of Basel
  4. Lionel Tintignac University of Basel
  5. Cristobal Tostado University of Basel
  6. Giusi Moffa University Hospital of Basel
  7. Andrea Bink University Hospital of Zurich
  8. Philippe Demougin University of Basel
  9. Suzanne Moes University of Basel
  10. Christoph Stippich Kliniken Schmieder Allensbach
  11. Simona Falbo University Hospital of Basel
  12. Heike Neddersen University Hospital of Basel
  13. Stephan Frank University Hospital of Basel
  14. Claudia Lengerke University of Basel
  15. Heiner Bucher University Hospital of Basel
  16. Paul Jenö University of Basel
  17. Marie-Francoise Ritz University of Basel
  18. Luigi Mariani University Hospital of Basel
  19. Jean-Louis Boulay University of Basel
Form of presentation Poster
  • Joint SSNR | SSNS
Abstract text Aims: Diffuse gliomas progress by invading neighboring brain tissue to promote post-operative relapse. Transcription factor gene SOX2 is highly expressed in invasive gliomas and maps to 3q26 together with the genes for the PI3K/AKT signaling activator PIK3CA, and those encoding effectors of mitochondria fusion and cell invasion inhibitors MFN1 and OPA1.
Methods: We aimed at investigating their respective roles in glioma cell invasion in vitro and by exploiting retrospective patient neuro-imaging data.
Results: Gene copy number analysis at 3q26 from 129 glioma patient biopsies revealed mutually exclusive SOX2 amplifications (26%) and OPA1 losses (19%). Both forced SOX2 expression and OPA1 inactivation increased LN319 glioma cell invasion. Conversely, pharmacological PI3K/AKT pathway inhibition decreased invasion and resulted in SOX2 nucleus-to-cytoplasm translocation in a mTORC1-independent manner, showing that PI3K/AKT signaling sustains SOX2 activity. Chromatin immuno-precipitation and luciferase reporter gene assays together demonstrated that SOX2 trans-activates PIK3CA and OPA1. Thus, SOX2 activates PI3K/AKT signaling in a positive feedback loop, while OPA1 deletion is interpreted to counter-act OPA1 trans-activation. Remarkably, neuro-imaging of human gliomas with high SOX2 or low OPA1 genomic imbalances revealed significantly larger necrotic tumor zone volumes, corresponding to higher invasive capacities of tumors.
Conclusions: Whereas glioma invasion is activated by an oncogenic PI3K/AKT-SOX2 loop, it is reduced by a cryptic tumor suppressor SOX2-OPA1 pathway. Thus, RTK/PI3K/AKT-SOX2 and mitochondria fission represent potential signaling networks to be targeted to control glioma invasion. In addition, our results indicate that necrosis volume is a potential surrogate marker for evaluation of invasion.